BioMarin Pharmaceutical Inc.
$54.33
▼
-0.53%
2026-04-22 10:12:13
www.biomarin.com
NMS: BMRN
Explore BioMarin Pharmaceutical Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$10.47 B
Current Price
$54.33
52W High / Low
$66.28 / $50.76
Stock P/E
30.1
Book Value
$31.65
Dividend Yield
—
ROCE
5.99%
ROE
5.94%
Face Value
—
EPS
$1.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3,221
Beta
0.29
Debt / Equity
10.56
Current Ratio
5.21
Quick Ratio
3.5
Forward P/E
8.1
Price / Sales
3.26
Enterprise Value
$9.57 B
EV / EBITDA
13.24
EV / Revenue
2.97
Rating
Buy
Target Price
$88.87
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 2. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 3. | OSR Holdings, Inc. | $0.6 | — | $19.87 M | — | 79.82% | -20.03% | $1.79 / $0.38 | $3.46 |
| 4. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 5. | Cocrystal Pharma, Inc. | $1.51 | — | $20.82 M | — | -120.22% | -1.11% | $2.67 / $0.86 | $0.46 |
| 6. | Agios Pharmaceuticals, Inc. | $27.07 | — | $1.54 B | — | -38.86% | -30.2% | $46 / $22.24 | $20.41 |
| 7. | Immunome, Inc. | $24.25 | — | $2.79 B | — | -35.12% | -52.09% | $27.65 / $6.96 | $5.61 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 874.57 M | 776.13 M | 825.41 M | 745.14 M | 747.31 M |
| Operating Profit | -44.6 M | -46.68 M | 276.87 M | 223.91 M | 161.37 M |
| Net Profit | -46.57 M | -30.74 M | 240.53 M | 185.69 M | 124.94 M |
| EPS in Rs | -0.24 | -0.16 | 1.25 | 0.97 | 0.65 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.22 B | 2.85 B | 2.42 B | 2.1 B |
| Operating Profit | 409.5 M | 474.24 M | 185.78 M | 57.41 M |
| Net Profit | 348.9 M | 426.86 M | 167.65 M | 141.56 M |
| EPS in Rs | 1.81 | 2.22 | 0.87 | 0.74 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.59 B | 6.99 B | 6.84 B | 6.38 B |
| Total Liabilities | 1.51 B | 1.33 B | 1.89 B | 1.77 B |
| Equity | 6.09 B | 5.66 B | 4.95 B | 4.6 B |
| Current Assets | 3.95 B | 3.23 B | 2.96 B | 2.75 B |
| Current Liabilities | 759.03 M | 606.99 M | 1.18 B | 588.88 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 827.99 M | 572.84 M | 159.26 M | 175.9 M |
| Investing CF | -414.24 M | 136.49 M | -111.24 M | -20.03 M |
| Financing CF | -42.39 M | -526.45 M | -18.73 M | -18.65 M |
| Free CF | 717.02 M | 475.42 M | 51.65 M | 44.36 M |
| Capex | -110.97 M | -97.42 M | -107.61 M | -131.54 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 17.97% | 15.42% | — | — |
| Earnings Growth % | 154.62% | 18.43% | — | — |
| Profit Margin % | 14.96% | 6.93% | 6.75% | — |
| Operating Margin % | 16.62% | 7.68% | 2.74% | — |
| Gross Margin % | 79.67% | 78.01% | 76% | — |
| EBITDA Margin % | 22.81% | 12.83% | 12.66% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.